Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s Eddingpharm Deal A Fresh Start For Ablynx’s Ozoralizumab

This article was originally published in PharmAsia News

Executive Summary

Ablynx has signed a deal with Chinese company Eddingpharm for certain Asian rights to its rheumatoid arthritis drug ozoralizumab, marking a fresh start for the anti-TNF nanobody after Pfizer backed out of a global deal in 2011.

You may also be interested in...



EOC Gears To Evolve Into Integrated Oncology Company

Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.

Commercial Partner Sought For Nasal Spray Claimed To ‘Prevent’ COVID-19

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.

Russia Prepares $10 COVID-19 Vaccine For International Launch

Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel